Phase I Study of Oral DFP-11207 in Solid Tumors

NCT ID: NCT02171221

Last Updated: 2019-01-29

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 23 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2014-06-30
• Study Completion Date: 2018-09-13

Brief Summary

This is a first-in-human, open label, single arm, sequential dose escalation and expansion study of oral DFP-11207 in patients with advanced solid tumors.

Detailed Description

The Phase I dose escalation portion of the study has been completed. The maximum tolerated dose (MTD)/recommended phase 2 dose (RP2D) has been determined. The study will now evaluate the effect of food on the pharmacokinetics of DFP-11207.

The food effect study is a two-step, two-way crossover design to evaluate the pharmacokinetics and bioavailability of oral DFP-11207 capsules. During Cycle 1, oral DFP-11207 capsules are to be taken daily (as a single dose or twice-daily [approximately 12 hours apart]) under fed/fasted conditions. After Cycle 1, the food effect study will be completed and patients will continue to take oral DFP-11207 capsules twice-daily (approximately 12 hours apart) for 28 days of a 28-day treatment cycle.

Conditions

Solid Tumors; Cancer

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Oral DFP-11207

DFP-11207: daily oral dosing, 28 day treatment cycle

Group Type: EXPERIMENTAL

Oral DFP-11207

Intervention Type: DRUG

Interventions

Oral DFP-11207

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Patients must have pathologically-confirmed solid tumors, refractory after standard therapy for the disease or for which conventional systemic chemotherapy is not reliably effective or no effective therapy is available.

2. Aged ≥ 18 years.

3. ECOG Performance Status of 0 or 1.

4. Adequate clinical laboratory values defined as:

• absolute neutrophil count ≥ 1.5 x 10^9/L
• platelets ≥ 100 x 10^9/L
• plasma creatinine ≤ 1.5 x upper limit of normal (ULN) for the institution
• bilirubin ≤ 1.5 x ULN
• alanine transaminase (ALT) and aspartate transaminase (AST) < 2.5 x ULN (< 5 x ULN if documented hepatic metastases)

5. Absence of uncontrolled intercurrent illnesses, including uncontrolled infections, cardiac conditions, or other organ dysfunctions.

6. Patients may have measurable or non-measurable disease as defined by RECIST 1.1.

7. Signed informed consent prior to the start of any study specific procedures.

8. Women of child-bearing potential must have a negative serum or urine pregnancy test. Male and female patients must agree to use acceptable contraceptive methods for the duration of the study and for at least one month after the last drug administration.

Exclusion Criteria

1. Known allergy to fluoropyrimidines or known dihydropyrimidine dehydrogenase (DPD) deficiency.

2. Patients will be excluded if they have received previous chemotherapy, immunotherapy, radiotherapy or any other investigational therapy within 4 weeks (6 weeks for nitrosoureas or mitomycin C) or 5 half-lives for non-cytotoxic agents prior to this study entry.

3. Extensive prior radiotherapy, more than 30% of bone marrow reserves, or prior bone marrow/stem cell transplantation.

4. Any concomitant condition that in the opinion of the Investigator could compromise the objectives of this study and the patient's compliance.

5. Pregnant or lactating individuals.

6. Current malignancies of another type, with the exception of adequately treated in situ cervical cancer, squamous cell and basal cell skin cancer or other malignancies with no evidence of disease for 2 years or more.

7. Known history of HIV, HBV or HCV infection.

8. Documented or known bleeding disorder.

9. Requirement for anticoagulation treatment that increases international normalized ratio (INR) or activated partial thromboplastin time (aPTT) above the normal range (low dose deep vein thrombosis (DVT) or line prophylaxis is allowed).

10. Clinically evident central nervous system metastases or leptomeningeal disease not controlled by prior surgery or radiotherapy; history of seizure disorder not controlled by anti-seizure medication at the time of enrollment.

11. Cardiac dysfunction defined as myocardial infarction within 6 months of study entry, New York Heart Association Class III or IV heart failure, uncontrolled dysrhythmias or poorly controlled angina.

12. History of serious ventricular arrhythmia (VT or VF, ≥ 3 beats in a row), QTc ≥ 450 msec for men and 470 msec for women, or LVEF ≤ 40% by MUGA or ECHO.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Delta-Fly Pharma, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Locations

MD Anderson Cancer Center

Houston, Texas, United States

Countries

United States

References

Ajani JA, Javle M, Eng C, Fogelman D, Smith J, Anderson B, Zhang C, Iizuka K. Phase I study of DFP-11207, a novel oral fluoropyrimidine with reasonable AUC and low Cmax and improved tolerability, in patients with solid tumors. Invest New Drugs. 2020 Dec;38(6):1763-1773. doi: 10.1007/s10637-020-00939-w. Epub 2020 May 6.

Reference Type: DERIVED

PMID: 32377978 (View on PubMed)

Other Identifiers

D13-11038

Identifier Type: -

Identifier Source: org_study_id